UPDATE 1-Pharming Q3 loss worse than forecast

* Q3 loss 8 million euros

* End-September cash position 10.6 million euros

(Adds detail)

AMSTERDAM, Oct 16 (Reuters) - Dutch biotechnology firm Pharming (PHAR.AS) reported a wider than forecast loss in the third quarter on high costs for getting approval for its flagship drug Rhucin.

The net loss was 8 million euros, compared with a loss of 7.5 million euros a year earlier and an average analyst forecast for 6.6 million.

Pharming's cash position at the end of September was 10.6 million euros, after an exchange programme for its 2007 convertible bonds aimed at improving its financial profile. [ID:nLL629947]

At the end of September, Pharming said the 70 million euros in 2007 convertibles had been reduced 10.9 million euros.

Pharming, which produces therapeutic proteins in milk of genetically modified animals, lodged a request for marketing approval of Rhucin with the EMEA at the start of September. [ID:nL3427348]

Pharming developed Rhucin to treat hereditary angioedema, characterised by acute attacks of painful swelling of the skin, intestine, mouth and throat.

(Reporting by Reed Stevenson; editing by John Stonestreet)